W. Wolfgang Fleischhacker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
W. Wolfgang Fleischhacker has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Martina Hummer
Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
5 shared publications Martina Hummer
Innsbruck Medical University
4 shared publicationsM Kurz
3 shared publicationsA Z Safferman
2 shared publicationsC Barnas
Universitätsklinik für Psychiatrie, Wien
2 shared publicationsGeorg Kemmler
2 shared publications
Latest Publications
- 1 March 2012
- Published by Taylor & Francis in Laterality
- Vol. 17 (2) , 217-224
Familial sinistrality and handedness in patients with first episode schizophrenia: The EUFEST study
The population with schizophrenia is characterised by a leftward shift in handedness—sinistrality. However, findings are inconsistent in chronic patients, and familial sinistrality (FS), defined as the presence of left-handed close relatives, might contribute to the discrepancies. Therefore the aim of this study was to investigate the strength of manual lateralisation in patients with first episode schizophrenia, taking into account familial sinistrality. The Edinburgh Inventory (EI) allowed us to categorise 179 patients from the EUFEST study and 189 controls presenting “strong handedness” (SH: EI absolute value between ∣81∣ and ∣100∣) or “weak-handedness” (WH: EI value between −80 and +80). The nominal logistic regression did not show an FS effect, but a nearly significant interaction between illness and FS (p =.07). There were fewer participants without FS presenting SH among patients (99/151: 65.6%) than among controls (134/164: 81.7%, p =.001). In contrast, the number of participants with FS presenting SH was similar between controls (68%) and patients (75%, p =.57). The presence of left-handed relatives (FS + ) tended to reduce manual lateralisation, but only in controls. This supports the notion that reduced manual lateralisation in schizophrenia is related to the illness rather than to familial left-handedness.
- 1 March 2012
- Published by Taylor & Francis in Laterality
- Vol. 17 (2) , 217-224
Familial sinistrality and handedness in patients with first episode schizophrenia: The EUFEST study
The population with schizophrenia is characterised by a leftward shift in handedness—sinistrality. However, findings are inconsistent in chronic patients, and familial sinistrality (FS), defined as the presence of left-handed close relatives, might contribute to the discrepancies. Therefore the aim of this study was to investigate the strength of manual lateralisation in patients with first episode schizophrenia, taking into account familial sinistrality. The Edinburgh Inventory (EI) allowed us to categorise 179 patients from the EUFEST study and 189 controls presenting “strong handedness” (SH: EI absolute value between ∣81∣ and ∣100∣) or “weak-handedness” (WH: EI value between −80 and +80). The nominal logistic regression did not show an FS effect, but a nearly significant interaction between illness and FS (p =.07). There were fewer participants without FS presenting SH among patients (99/151: 65.6%) than among controls (134/164: 81.7%, p =.001). In contrast, the number of participants with FS presenting SH was similar between controls (68%) and patients (75%, p =.57). The presence of left-handed relatives (FS + ) tended to reduce manual lateralisation, but only in controls. This supports the notion that reduced manual lateralisation in schizophrenia is related to the illness rather than to familial left-handedness.
- Open Access
- 1 October 2007
- Vol. 4 (4) , 86-88
Psychiatry in Austria.
Austria covers an area of some 84 000 km2 and has a population of 8.1 million. According to World Bank criteria, Austria is a high-income country. The overall health budget represents 8% of gross domestic product (World Health Organization, 2005). The state of Austria is divided into nine federal provinces, which have significant legislative rights, including in healthcare provision.
- 1 October 2007
- Vol. 4 (4) , 86-88
Open AccessPsychiatry in Austria.
Austria covers an area of some 84 000 km2 and has a population of 8.1 million. According to World Bank criteria, Austria is a high-income country. The overall health budget represents 8% of gross domestic product (World Health Organization, 2005). The state of Austria is divided into nine federal provinces, which have significant legislative rights, including in healthcare provision.
- Open Access
- 1 October 2007
- Published by Cambridge University Press (CUP) in International Psychiatry
- Vol. 4 (4) , 86-88
Psychiatry in Austria
Austria covers an area of some 84000 km2 and has a population of 8.1 million. According to World Bank criteria, Austria is a high-income country. The overall health budget represents 8% of gross domestic product (World Health Organization, 2005). The state of Austria is divided into nine federal provinces, which have significant legislative rights, including in healthcare provision.
- 1 October 2007
- Published by Cambridge University Press (CUP) in International Psychiatry
- Vol. 4 (4) , 86-88
Open AccessPsychiatry in Austria
Austria covers an area of some 84000 km2 and has a population of 8.1 million. According to World Bank criteria, Austria is a high-income country. The overall health budget represents 8% of gross domestic product (World Health Organization, 2005). The state of Austria is divided into nine federal provinces, which have significant legislative rights, including in healthcare provision.
- 13 March 2007
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 115 (4) , 310-319
Patterns of social distance towards people suffering from schizophrenia in Austria: a comparison between the general public, relatives and mental health staff
Objective: The aims of this study were to identify the different aspects of the attitudes towards people suffering from schizophrenia and to find factors influencing these attitudes – especially the willingness to contact people suffering from schizophrenia – as well as to obtain information on how to reduce stigma and discrimination.Method: We conducted a study to investigate these attitudes in Austria. A representative sample of the general public, different professional groups working in the field and relatives of mentally ill people were interviewed. The public, relatives and people working in the mental health field were asked a number of the same questions, to allow for comparisons between groups.Results: We found great differences in key dimensions of the attitude towards people suffering from schizophrenia between groups: these included different causal attributions to schizophrenia, different attitudes concerning the perceived success of the treatment of schizophrenia, different fears concerning perceived dangerousness and a different willingness to interact voluntarily with schizophrenia patients.Conclusion: The factors influencing the distance towards people suffering from schizophrenia differ between groups. Our findings should help to optimize campaigns fighting against stigma and discrimination.
- 13 March 2007
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 115 (4) , 310-319
Patterns of social distance towards people suffering from schizophrenia in Austria: a comparison between the general public, relatives and mental health staff
Objective: The aims of this study were to identify the different aspects of the attitudes towards people suffering from schizophrenia and to find factors influencing these attitudes – especially the willingness to contact people suffering from schizophrenia – as well as to obtain information on how to reduce stigma and discrimination.Method: We conducted a study to investigate these attitudes in Austria. A representative sample of the general public, different professional groups working in the field and relatives of mentally ill people were interviewed. The public, relatives and people working in the mental health field were asked a number of the same questions, to allow for comparisons between groups.Results: We found great differences in key dimensions of the attitude towards people suffering from schizophrenia between groups: these included different causal attributions to schizophrenia, different attitudes concerning the perceived success of the treatment of schizophrenia, different fears concerning perceived dangerousness and a different willingness to interact voluntarily with schizophrenia patients.Conclusion: The factors influencing the distance towards people suffering from schizophrenia differ between groups. Our findings should help to optimize campaigns fighting against stigma and discrimination.
- 1 November 2006
- Published by Springer Nature in Der Nervenarzt
- Vol. 77 (S03) , S77-S98
Pharmakotherapie der Schizophrenie
Das Management von Schizophreniepatienten ist eine der größten Herausforderungen in der Psychiatrie. Trotz der unbestrittenen Effektivität von Antipsychotika sind Patienten und Ärzte nach wie vor mit beträchtlichen Schwierigkeiten konfrontiert. Diese beziehen sich im Wesentlichen auf unvollständiges (oder ganz fehlendes) Ansprechen auf die Behandlung und die Unmöglichkeit individuell Wirksamkeit und Verträglichkeit vorherzusagen. In dieser Arbeit geben wir einen Überblick über die wichtigsten Elemente der pharmakologischen Behandlung der Erkrankung. Akut- und Langzeitmanagement sowie spezifische Behandlungsprobleme, die von akut erregten bis hin zu therapieresistenten Patienten rangieren, werden abgehandelt. Nach einer Übersicht über allgemeine Therapieprinzipien soll die vorliegende Arbeit spezifische Informationen über Wirksamkeit und Sicherheit von Antipsychotika vermitteln. Viele der zurzeit verfügbaren Behandlungsempfehlungen/Richtlinien basieren auf der Evidenz, die in diesem Manuskript zusammengefasst wird. Diese Übersicht soll dem Kliniker, der in die Behandlung von Schizophreniepatienten involviert ist, Leitfaden sein, unabhängig davon ob er im Rahmen einer Fachklinik oder als niedergelassener praktischer Arzt tätig ist. The management of schizophrenia patients remains one of the great challenges in psychiatry. Despite the undisputed effectiveness of antipsychotic drugs, patients and their physicians still face considerable difficulties mainly related to incomplete or lacking treatment response and the inability to predict the individual efficacy and tolerability. In this manuscript we review the key elements of pharmacological treatment of this disorder, encompassing acute and long-term management as well as specific management problems ranging from acutely violent patients to treatment-resistant subjects. Along with general treatment principles, the document provides specific information regarding efficacy and safety features of antipsychotics. Many of the currently available treatment recommendations/guidelines are based on the evidence reviewed here. This review is meant to serve as a guide for clinicians involved in managing schizophrenia, whether in a psychiatric hospital setting or as family physicians in private practice.
- 1 November 2006
- Published by Springer Nature in Der Nervenarzt
- Vol. 77 (S03) , S77-S98
Pharmakotherapie der Schizophrenie
Das Management von Schizophreniepatienten ist eine der größten Herausforderungen in der Psychiatrie. Trotz der unbestrittenen Effektivität von Antipsychotika sind Patienten und Ärzte nach wie vor mit beträchtlichen Schwierigkeiten konfrontiert. Diese beziehen sich im Wesentlichen auf unvollständiges (oder ganz fehlendes) Ansprechen auf die Behandlung und die Unmöglichkeit individuell Wirksamkeit und Verträglichkeit vorherzusagen. In dieser Arbeit geben wir einen Überblick über die wichtigsten Elemente der pharmakologischen Behandlung der Erkrankung. Akut- und Langzeitmanagement sowie spezifische Behandlungsprobleme, die von akut erregten bis hin zu therapieresistenten Patienten rangieren, werden abgehandelt. Nach einer Übersicht über allgemeine Therapieprinzipien soll die vorliegende Arbeit spezifische Informationen über Wirksamkeit und Sicherheit von Antipsychotika vermitteln. Viele der zurzeit verfügbaren Behandlungsempfehlungen/Richtlinien basieren auf der Evidenz, die in diesem Manuskript zusammengefasst wird. Diese Übersicht soll dem Kliniker, der in die Behandlung von Schizophreniepatienten involviert ist, Leitfaden sein, unabhängig davon ob er im Rahmen einer Fachklinik oder als niedergelassener praktischer Arzt tätig ist. The management of schizophrenia patients remains one of the great challenges in psychiatry. Despite the undisputed effectiveness of antipsychotic drugs, patients and their physicians still face considerable difficulties mainly related to incomplete or lacking treatment response and the inability to predict the individual efficacy and tolerability. In this manuscript we review the key elements of pharmacological treatment of this disorder, encompassing acute and long-term management as well as specific management problems ranging from acutely violent patients to treatment-resistant subjects. Along with general treatment principles, the document provides specific information regarding efficacy and safety features of antipsychotics. Many of the currently available treatment recommendations/guidelines are based on the evidence reviewed here. This review is meant to serve as a guide for clinicians involved in managing schizophrenia, whether in a psychiatric hospital setting or as family physicians in private practice.
- 1 May 2006
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 5 (3) , 232-238
Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other
Although the debate on whether new antipsychotics have advantages over the old neuroleptics has recently been refueled by the first publication of the Clinical Antipsychotic Trials of Intervention Effectiveness results, one of the new challenges in the pharmacological management of schizophrenia patients is to choose among the new-generation drugs. Earlier work has compared these medications primarily to traditional antipsychotics and until very recently there was little published information on the relative efficacy/safety of new-generation antipsychotics. This review covers studies wherein therapeutic effects and adverse events of these drugs in schizophrenia patients were compared in head-to-head studies and that were published in 2005. Information is clearly more homogenous on the safety profile side, while the available evidence still offers little help for the clinicians' daily struggles to find the optimally effective antipsychotic for an individual schizophrenia patient.
- 1 May 2006
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 5 (3) , 232-238
Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other
Although the debate on whether new antipsychotics have advantages over the old neuroleptics has recently been refueled by the first publication of the Clinical Antipsychotic Trials of Intervention Effectiveness results, one of the new challenges in the pharmacological management of schizophrenia patients is to choose among the new-generation drugs. Earlier work has compared these medications primarily to traditional antipsychotics and until very recently there was little published information on the relative efficacy/safety of new-generation antipsychotics. This review covers studies wherein therapeutic effects and adverse events of these drugs in schizophrenia patients were compared in head-to-head studies and that were published in 2005. Information is clearly more homogenous on the safety profile side, while the available evidence still offers little help for the clinicians' daily struggles to find the optimally effective antipsychotic for an individual schizophrenia patient.
- 1 October 2005
- Published by Elsevier in Schizophrenia Research
- Vol. 78 (2-3) , 147-156
The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial
- 1 October 2005
- Published by Elsevier in Schizophrenia Research
- Vol. 78 (2-3) , 147-156
The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial
- 1 August 2005
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 187 (2) , 131-136
Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year
Background The extent to which antipsychotics improve patients' well-being is uncertain.
- 1 August 2005
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 187 (2) , 131-136
Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year
Background The extent to which antipsychotics improve patients' well-being is uncertain.
- 7 April 2005
- Published by Georg Thieme Verlag KG in Psychiatrische Praxis
- Vol. 32 (S 1) , 25-30
Medikamentösinduzierte extrapyramidalmotorische Störungen: vermeiden, erkennen, behandeln
Akute extrapyramidalmotorische Störungen (EPMS) stellen eine häufige Nebenwirkung bei antipsychotischer Behandlung dar. EPMS führen zu reduzierter Lebensqualität und zu verminderter Compliance der Patienten. Dieser Artikel gibt einen Überblick über die unterschiedlichen Formen von EPMS, stellt die Vermeidung dieser Nebenwirkungen kurz dar, zeigt Diagnose- und Behandlungsprobleme auf, und weist auf die Bedeutung von prophylaktischen Maßnahmen hin. Die Antipsychotika der neueren Generation führen im Vergleich zu klassischen Antipsychotika deutlich seltener zu EPMS, wie zahlreiche Studien zeigen. Dennoch gibt es widersprüchliche Arbeiten zu diesem Thema. Dieser Artikel diskutiert einige dieser Ergebnisse und beleuchtet auch Probleme betreffend die Methodik der Erhebung von Nebenwirkungen. Acute extrapyramidal side-effects (EPS) are a common phenomenon of treatment with antipsychotics. They are associated with a substantial reduction of the patient's quality of life and of compliance with the treatment. This article gives an overview of the different forms of EPS. It outlines strategies to avoid these side-effects and discusses problems in diagnosis and treatment. In comparison to conventional compounds, the clearest advantage of new generation antipsychotics is a reduced risk of the occurrence of extrapyramidal side-effects (EPS). Many studies have found that newer antipsychotics have a lesser propensity to causes EPS. Nevertheless, there are some conflicting results on this topic. This article discusses some of these results and sheds light on methodological problems in the evaluation of side-effects of antipsychotic treatment.
- 7 April 2005
- Published by Georg Thieme Verlag KG in Psychiatrische Praxis
- Vol. 32 (S 1) , 25-30
Medikamentösinduzierte extrapyramidalmotorische Störungen: vermeiden, erkennen, behandeln
Akute extrapyramidalmotorische Störungen (EPMS) stellen eine häufige Nebenwirkung bei antipsychotischer Behandlung dar. EPMS führen zu reduzierter Lebensqualität und zu verminderter Compliance der Patienten. Dieser Artikel gibt einen Überblick über die unterschiedlichen Formen von EPMS, stellt die Vermeidung dieser Nebenwirkungen kurz dar, zeigt Diagnose- und Behandlungsprobleme auf, und weist auf die Bedeutung von prophylaktischen Maßnahmen hin. Die Antipsychotika der neueren Generation führen im Vergleich zu klassischen Antipsychotika deutlich seltener zu EPMS, wie zahlreiche Studien zeigen. Dennoch gibt es widersprüchliche Arbeiten zu diesem Thema. Dieser Artikel diskutiert einige dieser Ergebnisse und beleuchtet auch Probleme betreffend die Methodik der Erhebung von Nebenwirkungen. Acute extrapyramidal side-effects (EPS) are a common phenomenon of treatment with antipsychotics. They are associated with a substantial reduction of the patient's quality of life and of compliance with the treatment. This article gives an overview of the different forms of EPS. It outlines strategies to avoid these side-effects and discusses problems in diagnosis and treatment. In comparison to conventional compounds, the clearest advantage of new generation antipsychotics is a reduced risk of the occurrence of extrapyramidal side-effects (EPS). Many studies have found that newer antipsychotics have a lesser propensity to causes EPS. Nevertheless, there are some conflicting results on this topic. This article discusses some of these results and sheds light on methodological problems in the evaluation of side-effects of antipsychotic treatment.
- 1 January 2005
- Published by Springer Nature in CNS Drugs
- Vol. 19 (1) , 27-42
Switching Between Second-Generation Antipsychotics
The introduction of second-generation antipsychotics represents an important advance in the treatment of schizophrenia. Although these drugs are generally very effective, not all patients respond in the same way. Partial response with persistent positive and negative symptoms and residual symptoms may force physicians to change antipsychotic medication. As more and more second-generation antipsychotics are introduced, the need for practical guidelines on switching these medications becomes increasingly important. In this article we provide a short summary of the second-generation antipsychotics, focusing on efficacy, adverse effect profile and safety. Indications for switching antipsychotic medication are outlined, as well as recommendations when switching is disadvantageous. Three basic switching strategies (abrupt, gradual and overlapping switching) and their potential risks and benefits are described. We review the available evidence concerning techniques, problems and consequences when switching from one second-generation antipsychotic agent to another and discuss potential difficulties.
- 1 January 2005
- Published by Springer Nature in CNS Drugs
- Vol. 19 (1) , 27-42
Switching Between Second-Generation Antipsychotics
The introduction of second-generation antipsychotics represents an important advance in the treatment of schizophrenia. Although these drugs are generally very effective, not all patients respond in the same way. Partial response with persistent positive and negative symptoms and residual symptoms may force physicians to change antipsychotic medication. As more and more second-generation antipsychotics are introduced, the need for practical guidelines on switching these medications becomes increasingly important. In this article we provide a short summary of the second-generation antipsychotics, focusing on efficacy, adverse effect profile and safety. Indications for switching antipsychotic medication are outlined, as well as recommendations when switching is disadvantageous. Three basic switching strategies (abrupt, gradual and overlapping switching) and their potential risks and benefits are described. We review the available evidence concerning techniques, problems and consequences when switching from one second-generation antipsychotic agent to another and discuss potential difficulties.